Abstract
A 38-year-old Caucasian woman developed typical Graves’ hyperthyroidism and ophthalmopathy while being chronically treated for pemphigus vulgaris with low doses of glucocorticoids capable of effectively controlling skin disease. HLA typing showed positivity for DR3 and DR4, suggesting a genetic susceptibility for both Graves’ disease and pemphigus vulgaris. The apparent contradiction whereby thyroid autoimmune disease flared up during therapy with glucocorticoids, known for their immunosuppressive effects, may be related to the dose of steroids. It is possible that high doses of glucocorticoids, commonly employed in the treatment of severe Gravesα ophthalmopathy, might indeed suppress the disease, whereas the low doses used in this patient might precipitate or aggravate it.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boumpas D.T., Chrousos G.P., Wilder R.L., Cupps T.R., Balow J.E. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann. Intern. Med. 119: 1198, 1993.
Davies T.F. The pathogenesis of Graves’ disease. In: Braverman L.E., Utiger R.D. (Eds), Werner and Ingbar’s The Thyroid — A Fundamental and Clinical Text, ed 7. Lippincott-Raven Publ, Philadelphia, 1996, p. 525.
Bartalena L., Marcocci C, Bogazzi F., Bruno-Bossio G., Pinchera A. Glucocorticoid therapy of Graves’ ophthalmopathy. Exp. Clin. Endocrinol. 97: 320, 1991.
Terasaki P.I., McClelland J.D., Park M.S., Ozturk G., Iwaki Y. Microdroplet testing for HLA A, B, C and D antigens. Am. J. Clin. Pathol. 69: 103, 1978.
Parker F. Skin diseases of general importance. In: Bennett J.C, Plum F. (Eds), Cecil Textbook of Medicine, ed 20. Saunders Co., Philadelphia, 1996, p. 21.
McLachlan S.M., Rapoport B. Genetic factors in thyroid disease. In: Braverman L.E., Utiger R.C. (Eds), Werner and Ingba’s The Thyroid — A Fundamental and Clinical Text, ed 7. Lippincott-Raven Pub., Philadelphia, 1996, p. 483.
Bartalena L., Marcocci C., Bogazzi P., Panicucci M., Lepri A., Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N. Engl. J. Med. 321: 1349, 1989.
Firooz A., Mazhar A., Ahmed A. R. Prevalence of autoimmune diseases in the family members of patients with pemphigus vulgaris. J. Am. Acad. Dermatol. 31: 434, 1994.
Marcocci C., Bartalena L., Bogazzi F., Panicucci M., Pinchera A. Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol. (Copenh.) 120: 473, 1989.
Bartalena L., Bogazzi P., Tanda M.L., Manetti L., Dell’Unto E., Martine E. Cigarette smoking and the thyroid. Eur. J. Endocrinol. 133: 507, 1995.
Volpè R. Immunology of human thyroid dtsease. In: Volpè R. (ed). Autoimmunity in Endocrine Disèase. CRC Press, Boca Raton, 1990, p 73.
Werner S.C., Platman S.R. Remission of hyperthyroidism (Gravesè disease) and altered pattern of serum thyroxine binding induced by prednisone. Lancet ii: 7416, 1965.
Brown D.M., Lowman J.T. Thyrotoxicosis occurring in two patients on prolonged high doses of steroids. N. Engl. J. Med. 270: 278, 1964.
Lamberg B.A. Cushingès syndrome coexisting with hyperthyroidism. Acta Med. Scand. 175(Suppl. 412): 159, 1964.
Hofle G., Moncayo R., Baldissera I., Pfister R., Finkenstedt G. Endocrine ophthalmopathy in a patient under continuous immunosuppressive therapy after cardiac transplantation. Thyroid 5: 477, 1995.
Bartalena L., Marcocci C. Radioiodine therapy and Gravesè ophthalmopathy. Thyroid 6: 253, 1996 (Letter).
Bartalena L., Bogazzi F., Pecori F., Martino E. Gravesè disease occurring after subacute thyroiditis: report of a case and review of the literature. Thyroid 6: 345, 1996.
Blomgren H., Andersson B. Steroid sensitivity of the PHA and PWM responses in vitro. Exp. Cell Res. 97: 233, 1976.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bartalena, L., Bogazzi, F., Chiovato, L. et al. Graves’ hyperthyroidism and ophthalmopathy associated with pemphigus vulgaris: Onset of thyroid autoimmune disease during chronic low-dose glucocorticoid therapy. J Endocrinol Invest 20, 155–157 (1997). https://doi.org/10.1007/BF03346895
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346895